Program
osavampator
Also written as “NBI-1065845”, “TAK-653” and “Osavampator”.
Its studies are mostly in Depressive Disorder, Major · Depressive Disorder · Depressive Disorder, Treatment-Resistant, led by 2 companies.
Drug pageOsavampator: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurocrine Biosciences | 85 open or running | phase 3since Jan 15, 2025 | Sep 9, 2015 | Jul 2027phase 3 · NCT06911112 |
| Takedaits history only | 10 open or running | phase 2since Oct 13, 2017 | Oct 13, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Neurocrine Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 9, 2015First study: phase 1 study in Depressive DisorderFirst studyNCT02561156 · 88 enrolled · United Kingdom
- Jan 2, 2019Phase 1 study in Healthy VolunteersNCT03792672 · 24 enrolled · Netherlands
- Nov 18, 2021Phase 2 study in Depressive Disorder, MajorNCT05203341 · 183 enrolled · United States, Bulgaria, Czechia and more
- Aug 6, 2023Named osavampatorINNProposed as its International Nonproprietary Name in WHO's List 129 · before, NBI-1065845, TAK-653
- Jan 15, 2025Phase 3 study in Depressive Disorder, MajorNCT06786624 · 200 planned · United States
- Mar 28, 2025Phase 3 study in Depressive Disorder, MajorNCT06911112 · 200 planned · United States, Bulgaria, Lithuania and more
- Apr 30, 20252 phase 3 studies in Depressive Disorder, MajorNCT06966401, NCT06963021
- Sep 19, 2025Phase 3 study in Depressive Disorder, MajorNCT07196501 · 550 planned · United States, Australia, Bulgaria and more
Ahead
- Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06963021
- Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06911112
- Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06786624
- Jul 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT07196501
TargetBeta
“Glutamate receptor ionotropic AMPA positive allosteric modulator”ChEMBL 37, by rule
Studies
All 8 Neurocrine Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07196501Depressive Disorder, Major · United States, Australia, Bulgaria and more | 3 | Recruiting | Jul 2028 | 550 |
| NCT06966401Depressive Disorder, Major · United States, Australia, Belgium and more | 3 | Recruiting | May 2029 | 850 |
| NCT06963021Depressive Disorder, Major · United States, Belgium, Canada and more | 3 | Recruiting | Jul 2027 | 200 |
| NCT06911112Depressive Disorder, Major · United States, Bulgaria, Lithuania and more | 3 | Recruiting | Jul 2027 | 200 |
| NCT06786624Depressive Disorder, Major · United States | 3 | Recruiting | Jul 2027 | 200 |
| NCT05203341Depressive Disorder, Major · United States, Bulgaria, Czechia and more | 2 | Completed | Jan 10, 2024 | 183 |
| NCT03792672Healthy Volunteers · Netherlands | 1 | Completed | May 15, 2019 | 24 |
| NCT02561156Depressive Disorder · United Kingdom | 1 | Completed | Sep 11, 2017 | 88 |
How it is read
Names in the registry
- “NBI-1065845”, 5 entries
- “TAK-653”, 3 entries
- “Osavampator”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 6 studies
- Depressive Disorder, 1 study
- Depressive Disorder, Treatment-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.